|
Prostate cancer is a common urinary system tumors, the incidence rate also showed an increasing trend in our country in recent years, three of the largest in the male urinary tract tumors endocrine therapy for advanced androgen-sensitive prostate cancer treatment more obvious side effects caused by endocrine therapy, hot flashes, diminished libido and sexual performance, breast pain, fatigue, bloating, diarrhea, of which close to 80% of the incidence of hot flushes, decreased libido and sexual incidence of 20-30 % need to disable endocrine therapy before remission, while the withdrawal is likely to bring about the recurrence or progression of the disease. Research at home and abroad to show the prospects of Chinese medicine in the treatment of prostate cancer. Guangdong Provincial Hospital Urology in recent years, the use of Fuzhengyiliu combined endocrine therapy in the treatment of prostate cancer, shows good prospects. Purpose of this study in order to explore the Fuzhengyiliu side effects of prostate cancer endocrine therapy, and to explore the endocrine Fuzhengyiliu in patients with prostate cancer treatment side effects and improve the efficacy of the quality of life. Designed prospective study, the observed object Second Clinical Medical College of Guangzhou University of Traditional Chinese Medicine Hospital of Guangdong Province and Guangzhou Zhongshan Cancer Hospital the urology outpatient and inpatient department patients 48 cases, according to the patient's treatment wishes to establish a clinical control, respectively. divided into endocrine therapy alone (control group) the 18 cases TCM Fuzhengyiliu combined endocrine therapy group (treatment group) and 30 cases, the treatment time is more than three months. Review PSA before and after treatment, respectively, and fill in the prostate Ca patients questionnaire, the International Prostate Symptom Score (I-PSS) and AMS Scale (older men symptoms questionnaire). The results of the treatment group, excluding the two cases, the final effective cases, 46 cases, 28 cases of the treatment group, the control group, 18 patients. Statistical analysis, treatment group, rank and the mean pretreatment PSA value is 42.07, the rank after treatment and the mean was 14.93, a significant difference (P <0.01) compared to both; rank and the mean for the control group, pretreatment PSA value 27.5, the rank after treatment and the mean 9.5, comparing the two was statistically significant (P <0.01); treatment group endocrine therapy side effects overall incidence of 21.4%, the control group after treatment side effects The overall incidence rate of 72.2% two groups statistically significant difference (P <0.05); treatment group the incidence of hot flashes and fatigue, respectively, 17.9% and 0, the control group of hot flashes and fatigue of the incidence of 50% and 38.5%, respectively, the two between group compared to the incidence of hot flashes and fatigue statistically significant difference (P <0.05); I-PSS score sheet treatment group mean of 34.89 ± 3.50, a mean of 38.94 ± 3.96 in control group after treatment, two significant difference (P <0.05) groups compared; the MS Scale Display, the treatment group mean of 6.29 ± 1.78, control group after treatment a mean of 8.17 ± 1.89, the two groups have a significant difference (P <0.05 ). Conclusion Fuzhengyiliu combined endocrine therapy in reducing prostate cancer endocrine therapy side effects such as fatigue, hot flashes occur play a certain effect, can improve the patient's quality of life.
|